What is Rallybio Corp Annual Net Profit?

Rallybio Corp Annual Net Profit rose 22.52% in the last year to $57.78 M. Its sector's average net profit growth for the last fiscal year was -17.05%.

What is Rallybio Corp Price to Earning Ratio?

Rallybio Corp Price to Earning Ratio is -0.32, which is negative.

What is Rallybio Corp Stock Price?

Rallybio Corp Stock Price fell 71.52% and underperformed its sector by 73.51% in the past year.

What is Rallybio Corp Quarterly Net profit?

Rallybio Corp Quarterly Net profit rose 45.44% YoY to $11.04 M. Its sector's average net profit growth YoY for the quarter was -50.88%.

What is Rallybio Corp Debt to Equity Ratio?

Rallybio Corp Debt to Equity Ratio is zero as the company is debt-free.

What is Rallybio Corp Return on Equity(ROE)?

Rallybio Corp Return on Equity(ROE) for the last financial year was -68.85%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Rallybio Corp Mutual Fund Holding?

Rallybio Corp Mutual Fund Holding increased by 0.03% in the last quarter to 8.92.

What is Rallybio Corp Institutional Holding?

Rallybio Corp Institutional Holding remained the same in the last quarter at 81.5%.

How is the Rallybio Corp today?

The Rallybio Corp today is trading in the down by -19.64% at 0.45.

How has Rallybio Corp performed historically?

The Rallybio Corp is currently trading down -19.64% on an intraday basis in the past week the index fell -29.69%. The index has been down -55.45% in the past quarter and fell -71.52% in the past year. You can view this in the overview section.

Rallybio Corp XNAS: RLYB

Rallybio Corp Live Share Price Today, Share Analysis and Chart

Name: Rallybio Corp: Is Infosys Ltd. worth buying?
Item: Rallybio Corp
Rating: 0.84225
Author: Trendlyne DVM scores

Download real time

0.45 -0.11 (-19.64%)

New 52W Low today

182.5K XNAS Volume

High volume+loss today

XNAS 04 Apr, 2025 5:30 PM (EDT)

Rallybio Corp Key Metrics

My Metrics

Select

Market Capitalization Low in industry Unavailable in chosen country	18.7
PE TTM Negative PE TTM Unavailable in chosen country	-0.3
Price to Book Low in industry Unavailable in chosen country	0.3
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	81.5
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	45.4
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	22.5
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-30,547.4
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-9,511.9
Piotroski Score Low in industry Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-49.3
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-68.8
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-62.9

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

16.0 / 100

Technically Bearish

17.7 / 100

1Yr Price target upside is 1733%

4 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Rallybio Corp Stock Price Analysis

Day Price Range -19.6% 1 Day return Unavailable in chosen country	0.4 (LTP) 0.40.6 LowHigh
Week Price Range -29.7% 1 Week return Unavailable in chosen country	0.4 (LTP) 0.40.7 LowHigh
Month Price Range -37.5% 1 Month return Unavailable in chosen country	0.4 (LTP) 0.40.8 LowHigh
52 Week Price Range -71.5% 1 Year return Unavailable in chosen country	0.4 (LTP) 0.43.5 LowHigh

View full Share Price History

Rallybio Corp Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Rallybio Corp's Revenue was lower than average estimate 1 time in past 1 year

EPS forecast

QUARTER
ANNUAL

Current EPS

-1.3

Avg. Estimate

-1.3

Low Estimate

-2.4

High Estimate

-0.8

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 0.8% in FY25

Consensus Recommendation

5 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 5 analysts for Rallybio Corp is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Rallybio Corp Stock Analysis

Rallybio Corp stock analysis with key metrics, changes, and trends.

Rallybio Corp Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$57.78 M	22.52%	positive	Annual Net Profit rose 22.52% in the last year to $57.78 M. Its sector's average net profit growth for the last fiscal year was -17.05%.
Price to Earning Ratio	-0.32	-	negative	Price to Earning Ratio is -0.32, which is negative.
Stock Price	$0.45	-71.52%	negative	Stock Price fell 71.52% and underperformed its sector by 73.51% in the past year.
Quarterly Net profit	$11.04 M	45.44%	positive	Quarterly Net profit rose 45.44% YoY to $11.04 M. Its sector's average net profit growth YoY for the quarter was -50.88%.
Debt to Equity Ratio	-	-	positive	Debt to Equity Ratio is zero as the company is debt-free.
Return on Equity(ROE)	-68.85 %	-68.85%	negative	Return on Equity(ROE) for the last financial year was -68.85%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	8.92 %	0.03%	positive	Mutual Fund Holding increased by 0.03% in the last quarter to 8.92.
Institutional Holding	81.50 %	0%	neutral	Institutional Holding remained the same in the last quarter at 81.5%.

VIEW LESS

Loading data..

Rallybio Corp - Company Profile

What does Rallybio Corp do?

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Rallybio Corp Management structure

All Gross Remunerations are in USD

Mr. Jonathan I. Lieber, M.B.A.

Principal Accounting Officer, Chief Financial Officer and Treasurer

2024

Gross Remuneration

Year

Dr. Stephen Uden, M.D.

Chief Executive Officer, President and Director

2024

Gross Remuneration

2024

Gross Remuneration

Year

Rallybio Corp Live Share Price Today, Share Analysis and Chart

New 52W Low today

High volume+loss today

Rallybio Corp Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Rallybio Corp Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Rallybio Corp Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Rallybio Corp's Revenue was lower than average estimate 1 time in past 1 year

EPS forecast

EPS is expected to reduce by 0.8% in FY25

Consensus Recommendation

The consensus recommendation from 5 analysts for Rallybio Corp is STRONG BUY

Rallybio Corp Stock Analysis

Rallybio Corp stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 22.52% in the last year to $57.78 M. Its sector's average net profit growth for the last fiscal year was -17.05%.

Price to Earning Ratio is -0.32, which is negative.

Stock Price fell 71.52% and underperformed its sector by 73.51% in the past year.

Quarterly Net profit rose 45.44% YoY to $11.04 M. Its sector's average net profit growth YoY for the quarter was -50.88%.

Debt to Equity Ratio is zero as the company is debt-free.

Return on Equity(ROE) for the last financial year was -68.85%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.03% in the last quarter to 8.92.

Institutional Holding remained the same in the last quarter at 81.5%.

Rallybio Corp - Company Profile

What does Rallybio Corp do?

Rallybio Corp Management structure

Mr. Jonathan I. Lieber, M.B.A.

Principal Accounting Officer, Chief Financial Officer and Treasurer

Dr. Stephen Uden, M.D.

Chief Executive Officer, President and Director

Rallybio Corp Board of directors

Dr. Martin W. Mackay, PhD

Chairman of the Board

Dr. Kush M. Parmar, M.D.,PhD

Independent Director

Dr. Stephen Uden, M.D.

Chief Executive Officer, President and Director

Mr. Ronald M. Hunt, M.B.A.

Independent Director

Dr. Robert Hopfner, M.B.A.

Independent Director

Ms. Christine A. Nash, M.B.A.

Independent Director

Rallybio Corp FAQ

How is Rallybio Corp today?

Rallybio Corp today is trading in the red, and is down by -19.64% at 0.45.

How has Rallybio Corp performed historically?

Rallybio Corp is currently trading down -19.64% on an intraday basis. In the past week the stock fell -29.69%. stock has been down -55.45% in the past quarter and fell -71.52% in the past year. You can view this in the overview section.